Compare CVRX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | ICCC |
|---|---|---|
| Founded | 2000 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.3M | 93.1M |
| IPO Year | 2021 | 1995 |
| Metric | CVRX | ICCC |
|---|---|---|
| Price | $2.57 | $9.88 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $10.50 | N/A |
| AVG Volume (30 Days) | ★ 541.2K | 12.4K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.02 | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $56,651,000.00 | $26,493,169.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | ★ N/A | $24.21 |
| Revenue Growth | 10.45 | ★ 51.64 |
| 52 Week Low | $2.20 | $4.52 |
| 52 Week High | $11.30 | $12.10 |
| Indicator | CVRX | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 41.20 |
| Support Level | $2.20 | $9.39 |
| Resistance Level | $3.19 | $10.16 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 9.68 | 32.86 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.